JP Morgan Chase
NPCE icon

JP Morgan Chase’s Neuropace NPCE Stock Holding History

JP Morgan Chase’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
141,141
+10,215
+8% +$153K ﹤0.01% 4173
2025
Q4 		$2.02M Buy
130,926
+120,657
+1,175% +$1.61M ﹤0.01% 4061
2025
Q3 		$106K Sell
10,269
-1,374
-12% -$13K ﹤0.01% 5869
2025
Q2 		$130K Sell
11,643
-32,149
-73% -$402K ﹤0.01% 5480
2025
Q1 		$538K Sell
43,792
-21,034
-32% -$263K ﹤0.01% 4722
2024
Q4 		$725K Buy
64,826
+52,829
+440% +$459K ﹤0.01% 4835
2024
Q3 		$83.6K Buy
11,997
+6,181
+106% +$45.2K ﹤0.01% 5768
2024
Q2 		$44K Sell
5,816
-26,299
-82% -$265K ﹤0.01% 5906
2024
Q1 		$424K Buy
32,115
+20,755
+183% +$296K ﹤0.01% 4894
2023
Q4 		$117K Buy
+11,360
New +$90.6K ﹤0.01% 5659
2022
Q2 		– Sell
-3,330
Closed -$27K – 6743
2022
Q1 		$27K Sell
3,330
-1,622
-33% -$14K ﹤0.01% 6005
2021
Q4 		$50K Buy
4,952
+2,278
+85% +$29.6K ﹤0.01% 5943
2021
Q3 		$42K Sell
2,674
-5,319
-67% -$112K ﹤0.01% 5885
2021
Q2 		$191K Buy
+7,993
New +$186K ﹤0.01% 5270

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

JP Morgan Chase's NPCE Position: Q1 2026 in Review

JP Morgan Chase increased its Neuropace (NPCE) stake by 7.8% in Q1 2026, buying an estimated $153K and bringing the position to 141,141 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #4173.

JP Morgan Chase first reported a position in NPCE in Q2 2021 and has held it in 14 quarters since. The position peaked at $2.02M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • JP Morgan Chase held 141,141 shares of Neuropace worth $1.81M as of Q1 2026.
  • JP Morgan Chase bought 10,215 Neuropace shares in Q1 2026, an estimated $153K.
  • Neuropace made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4173 holding.
  • JP Morgan Chase first reported a position in Neuropace in Q2 2021 and has held it in 14 quarters since.
  • JP Morgan Chase's Neuropace position peaked at $2.02M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.